Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

BMC Cancer

Bi-Cheng Wang¹  Guo-He Lin²  Bo-Ya Xiao³ 

[1] Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology;Department of Oncology, the Second Affiliated Hospital of Anhui Medical University;Eastern Hepatobiliary Surgery Hospital, Second Military Medical University;

关键词: Ewing sarcoma;    Irinotecan;    Temozolomide;    Chemotherapy;    Integrated analysis;   

DOI  :  10.1186/s12885-022-09469-5

来源: DOAJ

【 摘 要 】

Highlights 1. Nearly 44% of relapsed Ewing sarcoma patients achieved an ORR after IT treatment. 2. Relapsed Ewing sarcoma treated with IT had an over 66% DCR. 3. IT chemotherapy caused low incidences of neutropenia, thrombocytopenia, and diarrhea in treating relapsed Ewing sarcoma.

【 授权许可】

Unknown